Equity Profile

ASND

Ascendis Pharma A/S

Health CareBiotechnology$17.4B

Aug13Thu

Pre-Earnings Brief

UpcomingQ2-2026Pre-Market9:00 AM EDT

Company Snapshot

Ascendis Pharma A/S is a biotechnology company focused on developing innovative therapies for rare diseases and endocrine disorders. As part of the health care sector, its advancements in biotechnology are crucial for improving patient outcomes and addressing unmet medical needs.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and product adoption, essential for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ASND Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+528.60%

Avg Stock Reaction

+0.76%

Last Quarter Recap

In Q1-2026, Ascendis Pharma reported an impressive EPS of $11.46, significantly exceeding expectations. However, revenue details were not disclosed, leaving some uncertainty about overall performance.

Management Promises & Guidance

Focus on advancing clinical trials for key therapies.
Commitment to maintaining strong R&D investment.
Plans to enhance market access for existing products.

Expectations

Wall Street Expectations

Overall, expectations are mixed as investors await clarity on revenue and future guidance. The strong EPS surprise last quarter has raised hopes for continued positive momentum.

Bull Case

If Ascendis continues to deliver strong earnings and provides positive guidance, it could signal robust demand for its therapies and lead to a significant stock rally.

Bear Case

Conversely, if the company fails to meet revenue expectations or provides cautious guidance, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the revenue figures be for Q2-2026?

Revenue is crucial for assessing the company's growth trajectory and market acceptance of its products.

How much will R&D spending increase this quarter?

Increased R&D spending can indicate a strong commitment to innovation, which is vital for a biotech company's future.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of Ascendis' recent product developments, which could drive stronger-than-expected revenue growth.

Supporting Evidence

The last quarter's EPS surprise indicates potential for continued strong performance.

Options pricing suggests higher volatility, hinting at significant market expectations.

Historical trends show that biotech companies often exceed revenue expectations following strong EPS.

Key Risk

If revenue growth comes in below expectations, it could undermine the positive outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to sustain growth and manage R&D investments effectively.

Bull Confirmed If

Revenue growth of at least 20% quarter-over-quarter would confirm the bullish outlook.

Bear Confirmed If

Any revenue decline or insufficient guidance could confirm the bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±9.25%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±9.3% while ASND has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

41.3%

Calls (3K)P/C Ratio: 5.70Puts (200)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ascendis beats expectations, history suggests a potential stock increase of around 4.71%, confirming positive momentum.

In-Line / Cautious

If results are in line but cautious, the stock may experience muted movement as investors digest the commentary.

Miss

A miss could lead to a decline of approximately 1.60%, reflecting disappointment in the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue figures for Q2-2026.
2Updates on clinical trial progress for key therapies.
3Insights into R&D spending plans moving forward.
4Any new partnerships or collaborations announced.
5Management's outlook on market conditions and competition.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and financial health, which investors closely monitor.

N/A

Revenue Growth

Revenue growth reflects the company's ability to expand its market presence and product adoption, essential for long-term success.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

ASND Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

+528.60%

Avg Stock Reaction

+0.76%

Last Quarter Recap

Management Promises & Guidance

Focus on advancing clinical trials for key therapies.
Commitment to maintaining strong R&D investment.
Plans to enhance market access for existing products.

Expectations

Wall Street Expectations

Overall, expectations are mixed as investors await clarity on revenue and future guidance. The strong EPS surprise last quarter has raised hopes for continued positive momentum.

Bull Case

If Ascendis continues to deliver strong earnings and provides positive guidance, it could signal robust demand for its therapies and lead to a significant stock rally.

Bear Case

Conversely, if the company fails to meet revenue expectations or provides cautious guidance, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the revenue figures be for Q2-2026?

Revenue is crucial for assessing the company's growth trajectory and market acceptance of its products.

How much will R&D spending increase this quarter?

Increased R&D spending can indicate a strong commitment to innovation, which is vital for a biotech company's future.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate the impact of Ascendis' recent product developments, which could drive stronger-than-expected revenue growth.

Supporting Evidence

The last quarter's EPS surprise indicates potential for continued strong performance.

Options pricing suggests higher volatility, hinting at significant market expectations.

Historical trends show that biotech companies often exceed revenue expectations following strong EPS.

Key Risk

If revenue growth comes in below expectations, it could undermine the positive outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around the company's ability to sustain growth and manage R&D investments effectively.

Bull Confirmed If

Revenue growth of at least 20% quarter-over-quarter would confirm the bullish outlook.

Bear Confirmed If

Any revenue decline or insufficient guidance could confirm the bearish sentiment.

Pre-Earnings Positioning

Options Market

Implied Move

±9.25%

Historical Avg

±2.8%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings announcement.

Options are pricing ±9.3% while ASND has averaged ±2.8% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.5%

30d HV

41.3%

Calls (3K)P/C Ratio: 5.70Puts (200)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Ascendis beats expectations, history suggests a potential stock increase of around 4.71%, confirming positive momentum.

In-Line / Cautious

If results are in line but cautious, the stock may experience muted movement as investors digest the commentary.

Miss

A miss could lead to a decline of approximately 1.60%, reflecting disappointment in the company's performance.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Details on revenue figures for Q2-2026.
2Updates on clinical trial progress for key therapies.
3Insights into R&D spending plans moving forward.
4Any new partnerships or collaborations announced.
5Management's outlook on market conditions and competition.